Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia;Recomendações para o diagnóstico, tratamento e monitorização da leucemia mielóide crónica

Acta Medica Portuguesa

Volumn 22, Issue 5, 2009, Pages 537-544

  Almeida, António ^a   Castro, Isabel ^b   Coutinho, Jorge ^c   Guerra, Lurdes ^d   Marques, Herlander ^e   Pereira, Ana Marques ^f  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e HOSPITAL DE BRAGA   (Portugal)

^f HOSPITAL GARCIA DE ORTA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DRUG TOLERABILITY; HUMAN; PATIENT MONITORING; PORTUGAL; TREATMENT OUTCOME;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC;

EID: 77149124911     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. QUINTÁS-CARDAMA A, CORTES J: Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113(8):1619-30
2. FADERL S, TALPAZ M, ESTROV Z et al: The biology of chronic myeloid leukemia. N Engl J Med 1999;341(3):164-172
3. Surveillance Epidemiology and End Results (SEER) - Stat Fact Sheets. Disponível em http://seer.cancer.gov/statfacts/html/ cmyl.html (acedido em Abril 2009)
4. SAWYERS CL. Chronic Myeloid Leukemia. N Engl J Med 1999;340(17):1330-40
5. CORTES J, KANTARJIAN HM, GIRALT S, TALPAZ M: Natural history and staging of chronic myelogeneous leukaemia. Baillieres Clin Haematol 1997;10(2):277-90
6. O'BRIEN SG, GUILHOT F, LARSON RA et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11):994-1004
7. DRUKER BJ, GUILHOT F, O'BRIEN SG et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17
8. MARIN D, MILOJKOVIC D, OLAVARRIA E et al: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112(12):4437-44
9. SHAH NP, KANTARJIAN HM, KIM DW et al: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):3204-12
10. KANTARJIAN H, PASQUINI R, HAMERSCHLAK N et al: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109(12):5143-50
11. QUINTÁS-CARDAMA A, CORTES J: Nilotinib therapy in chronic myelogeneous leukaemia. Drugs of today 2007;43(10):691-702. Disponível em www.prous.com/journals
12. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, V.2.2009. Disponível em http://www.nccn.org/professionals/ physician-gls/PDF/cml. pdf; (Acedido em Abril 2008)
13. GRATWOHL A, BRAND R, APPERLEY J et al: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91(4):513-521
14. BACCARANI M, SAGLIO G, GOLDMAN J et al: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the Eur LeukemiaNet. Blood 2006;108(6):1809-20
15. SOKAL JE, COX EB, BACCARANI M et al: Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984;63:789-799
16. HASFORD J, PFIRRMANN M, HEHLMANN R et al: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90:850-8
17. Chronic Myeloid Leukemia Calculation of Relative Risk (RR). Disponível em http://www.leukemia-net.org/content/leukemias/ cml/cml-score/ (Acedido em Março 2009)
18. JAFFE E, HARRIS N, STEIN H, VARDIMAN J: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tisues. Lyon: IARC Press 2001;31-7
19. GRATWOHL A, HERMANS J. GOLDMAN JM et al: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352(9134):1087-92
20. PASSWEG JR, WALKER I, SOBOCINSKI KA et al: Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004;125;613-620
21. Resumo das Características do Medicamento SPRYCEL® . Disponível em http://www.emea.europa.eu/humandocs/PDFs/EPAR/ sprycel/H-709-PI-pt.pdf (Acedido em Abril 2009)
22. Resumo das Características do Medicamento TASIGNA® . Disponível em http://www.emea.europa.eu/humandocs/PDFs/EPAR/ tasigna/H-798-PI-pt.pdf
23. KANTARJIAN H, SCHIFFER C, JONES D et al: Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111(4):1774-80
24. Resumo das Características do Medicamento GLIVEC® . Disponível em http://www.emea.europa.eu/humandocs/PDFs/EPAR/ glivec/H-406-PI-pt.pdf (Acedido em Abril 2009)
25. JABBOUR E, CORTES JE, KANTARJIAN HM: Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc 2009; 84(2):161-9
26. VALENT P, LION T, WOLF D et al: Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. WKW: Middle Eur J Med 2008;120:697-709
27. BACCARANI M, PANE F, SAGLIO G: Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;93(2):161-6
28. BRANFORD S, RUDZKI Z, WALSH S et al: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102(1):276-283
29. SOVERINI S, MARTINELLI G, ROSTI G et al: ABL mutations in late chronic phase chronic myeloid leukemia patients with upfront cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukaemia. J Clin Oncol 2005;23(18):4100-9
30. REDAELLI S, PIAZZA R, ROSTAGNO R et al: Activity of bosutinib, dasatinib and nilotinib against 18 imatinib resistant BCR/ ABL mutants - JCO 2008 In press. Disponível em http://www.iltecml. org/TKI-table.pdf (Acedido em Julho 2009)
31. DEININGER M, MAURO M, MATLOUB Y: Prevalence of T315I, dasatinib-specific resistant mutations (F317L, V299L, and T315A), and nilotinib-specific resistant mutations (P-loop and F359) at the time of imatinib resistance in chronic-phase Chronic Myeloid Leukemia (CP-CML). AHS 2008; abst 3236
32. QUINTÁS-CARDAMA A, KANTARJIAN H, O'BRIEN S, et al: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25(25):3908-14
33. PYE SM, CORTES J, AULT P et al: The effects of imatinib on pregnancy outcome. Blood 2008;111(12):5505-8
34. QUINTÁS-CARDAMA A, KANTARJIAN HM, CORTES J: Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukaemia. Cancer Control 2009;16(2):122-131
35. JABBOUR E, CORTES J, KANTARJIAN HM et al: Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006;108(4):1421-23